MedTrace Logo

Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies

NCT05528887 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-09-06

No results posted yet for this study

Summary

The primary purpose of this study is to determine the safety and efficacy of novel autologous CAR-T cells in patients with relapsed/refractory hematological malignancies.

Conditions

Interventions

BIOLOGICAL

Autologous CAR-T cells

D0: CAR-T cells will be infused intravenously.

DRUG

Fludarabine

D-5 to D-3: Fludarabine (30 mg/m\^2/day) will be administered intravenously for 3 days.

DRUG

Cyclophosphamide

D-5 to D-3: Cyclophosphamide (500 mg/m\^2/day) will be administered intravenously for 3 days.

Sponsors & Collaborators

  • UTC Therapeutics Inc.

    collaborator INDUSTRY

  • The Affiliated People's Hospital of Ningbo University

    lead OTHER_GOV

Principal Investigators

  • Ying Lu · The Affiliated People's Hospital of Ningbo University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-16
Primary Completion
2024-06-30
Completion
2026-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05528887 on ClinicalTrials.gov